ClinicalTrials.gg
CompletedNCT03903562Updated Apr 6, 2026Results posted

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

A Phase 3 interventional study of V503 in Papillomavirus Infections, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in China. Open to female participants aged 9 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,990
Allocation
Not applicable
Ages
9 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Enrollment
9th of 31
1,990 · median 700
Started
2019
with 1 other
Phase 3
16 of 31
2 open now
Registered
10th of 31
by date
Lead sponsor
15 of 31
Merck Sharp & Dohme LLC

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 9th largest by enrollment, is one of 2 that started in 2019, is one of 16 in phase 3, and was the 10th registered.

Papillomavirus Infections

580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 9 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

This study investigates the immunogenicity and safety of the 9vHPV vaccine in healthy Chinese females 9 to 45 years of age. The study consists of Stage I (Day 1 to Month 7) and Stage II (post Month 7 to Month 60). Stage II will report the long-term immunogenicity and safety in the 9-19 year-old age group only. The dual-primary hypotheses of Stage I are that 9vHPV vaccine induces non-inferior immune responses in females 9 to 19 years of age who are seronegative at Day 1 to the relevant HPV type compared to females 20 to 26 years of age who are seronegative at Day 1 to the relevant HPV type, as measured by anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 GMTs at 1 month post Dose 3, and 9vHPV vaccine induces non-inferior immune responses in females 27 to 45 years of age who are seronegative at Day 1 to the relevant HPV type compared to females 20 to 26 years of age who are seronegative at Day 1 to the relevant HPV type, as measured by the seroconversion percentages to each of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 1 month post Dose 3. (Each vaccine component will be analyzed separately.)

03

Conditions studied

  • Papillomavirus Infections
04

Who can participate

Ages eligible
9 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is a Chinese female judged to be in good physical health based on medical history and physical examination
  • Not a woman of (WOCBP) or if of WOCBP, has not had sex with males or has had sex with males and used effective since the first day of participant's last menstrual period through Day 1. And the participant understands and agrees that during the Day 1 through Month 7 period, she should not have sexual intercourse with males without effective contraception, and that the use of the rhythm method, withdrawal, and emergency contraception are not acceptable methods
  • Has a lifetime history of 0 to 4 male and/or female sexual partners at the time of enrollment. Male partner is defined as someone with whom the participant has penile penetrative sexual intercourse. Female partner is defined as someone who has contacted, either by penetrative (with fingers or other objects) or non-penetrative means, the participant's genitalia during sexual activity

Exclusion criteria

Exclusion Criteria

  • Known allergy to any vaccine component, including aluminum, yeast, or BENZONASE™ (nuclease, Nycomed™). An allergy to vaccine components is defined as an allergic reaction that met the criteria for serious adverse event
  • History of severe allergic reaction (e.g. swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention
  • Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
  • Has a fever (defined as an axillary temperature ≥37.1°C) within 24 hours prior to the Day 1 vaccination
  • Has any history of abnormal Pap test showing squamous intraepithelial lesion (SIL) or atypical squamous cells - undetermined significance (ASC-US), atypical squamous cells - cannot exclude HSIL (ASC-H), atypical glandular cells, or showing cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ or cervical cancer
  • History of external genital wart, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), vulvar cancer or vaginal cancer
  • History of a positive test for HPV
  • Currently or has been diagnosed as having congenital or acquired immunodeficiency, (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other condition
  • History of splenectomy
  • Donated blood within 1 week prior to the Day 1 vaccination, or intends to donate during Day 1 through Month 7 of the study
  • Expecting to donate eggs during Day 1 through Month 7 of the study
  • Pregnant
  • Receiving or has received in the year prior to Day 1 vaccination the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (Arava™), tumor necrosis factor (TNF)-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan™]), intravenous gamma globulin (IVIG), antilymphocyte sera, or other therapy known to interfere with the immune response. With regard to systemic , a participant will be excluded if she is currently receiving steroid therapy, has recently (defined as within 2 weeks of Day 1 vaccination) received such therapy, or has received 2 or more courses of corticosteroids (orally or parenterally) lasting at least 1 week in duration in the year prior to Day 1 vaccination. Participants using inhaled, nasal or topical corticosteroids are considered eligible for the study
  • Has received immune globulin product (including RhoGAM™ or blood-derived product other than IVIG within 6 months prior to Day 1 vaccination, or plans to receive any such product during Day 1 through Month 7 of the study
  • Has received a marketed HPV vaccine, or has participated in an HPV vaccine clinical trial and has received either active agent or placebo
  • Has received inactivated or recombinant vaccines within 14 days prior to Day 1 vaccination or has received within 21 days prior to Day 1 vaccination
  • Concurrently enrolled in clinical studies of interventional agents
  • A user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,990 participants (actual)

Study arms

  • Experimental
    V503

    V503 administered as a 0.5 mL intramuscular injection at Day 1, Month 2 and Month 6.

    Biological: V503

Interventions

  • BiologicalV503

    0.5 mL 9vHPV VLP Vaccine

06

What researchers measure

Primary outcomes

  1. Stage I: Competitive Luminex Immunoassay (cLIA) Geometric Mean Titers (GMTs) for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age and 20 to 26 Years of Age: Month 7

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as milli Merck units/mL (mMU/mL).

    Time frame: 1 month post vaccination 3 (Month 7)

  2. Stage I: Percentage of Participants 27 to 45 Years of Age and 20 to 26 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: 1 month post vaccination 3 (Month 7)

  3. Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 12

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: Month 12

  4. Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 24

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: Month 24

  5. Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 36

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: Month 36

  6. Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 48

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: Month 48

  7. Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 60

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: Month 60

  8. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 12

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 12

  9. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 24

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 24

  10. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 36

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥65, 37, 79, 85, 46, 26, 21, 30 and 31 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 36

  11. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 48

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥34, 25, 32, 26, 15, 10, 10, 14 and 10 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 48

  12. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 60

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥34, 25, 32, 26, 15, 10, 10, 14 and 10 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 60

  13. Stage II: Immunoglobulin G Luminex Immunoassay (IgG LIA) GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 12

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL. Although the same name (mMU/mL) is used for the unit of measurement in both cLIA and IgG LIA, the 'cLIA mMU/mL' and the 'IgG LIA mMU/mL' are actually different units of measurement and cannot be directly compared.

    Time frame: Month 12

  14. Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 24

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: Month 24

  15. Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 36

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: Month 36

  16. Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 48

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: Month 48

  17. Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 60

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: Month 60

  18. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 12

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 12

  19. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 24

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 24

  20. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 36

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 36

  21. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 48

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 48

  22. Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 60

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: Month 60

Secondary outcomes

  1. Stage I: Percentage of Participants 9 to 19 Years of Age and 20 to 26 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: 1 month post vaccination 3 (Month 7)

  2. Stage I: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 15 Years of Age and 20 to 26 Years of Age: Month 7

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type were expressed as mMU/mL. As pre-specified per protocol, participants 20 to 26 years of age and a subset of participants 9 to 15 years of age were included in the analysis.

    Time frame: 1 month post vaccination 3 (Month 7)

  3. Stage I: Percentage of Participants 9 to 15 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively. As pre-specified per protocol, a subset of participants 9 to 15 years of age were included in the analysis.

    Time frame: 1 month post vaccination 3 (Month 7)

  4. Stage I: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 27 to 45 Years of Age: Month 7

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type were expressed as mMU/mL.

    Time frame: 1 month post vaccination 3 (Month 7)

  5. Stage I: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age, 20 to 26 Years of Age, and 27 to 45 Years of Age: Month 7

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

    Time frame: 1 month post vaccination 3 (Month 7)

  6. Stage I: Percentage of Participants 9 to 19 Years of Age, 20 to 26 Years of Age, and 27 to 45 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7

    The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

    Time frame: 1 month post vaccination 3 (Month 7)

  7. Stage I: Percentage of Participants Who Experience at Least 1 Solicited Injection-site Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. The participant or the parent/guardian of the participant was to record the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 8 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, swelling and induration) is reported.

    Time frame: Up to 8 days post any vaccination (up to ~Day 192)

  8. Stage I: Percentage of Participants Who Experience at Least 1 Systemic AE

    An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. The percentage of participants with a systemic AE is reported.

    Time frame: Up to 31 days post any vaccination (Up to ~Month 7)

  9. Stage I: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. The percentage of participants that experienced 1 or more SAEs is reported.

    Time frame: Day 1 to Month 7

  10. Stage I: Percentage of Participants With Elevated Axillary Temperature (≥37.1 C)

    Participant or participant's legally acceptable representative will be asked to record axillary temperature in the evening after each study vaccination and daily, at the same time of day whenever possible, for 8 days after each study vaccination in the VRC. The percentage of participant's who had an axillary temperature ≥37.1°C is reported.

    Time frame: Up to 8 days post any vaccination (Up to ~Day 192)

  11. Stage II: Percentage of Participants 9 to 19 Years of Age Who Experience at Least 1 Serious Adverse Event (SAE): Month 7 to Month 60

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. The percentage of participants that experienced 1 or more SAEs is reported.

    Time frame: Month 7 to Month 60

07

Results

Posted Apr 6, 2026

Participant flow

Stage I
Participant flow — Stage I
Milestone9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of Age
Started690650650
Vaccination 1688650650
Vaccination 2683647644
Vaccination 3682635641
9 to 15 years of age who received at least 1 vaccination45800
Completed682635641
Not completed8159
Withdrew: Withdrawal by parent/guardian300
Withdrew: Withdrawal by subject5159
Stage II
Participant flow — Stage II
Milestone9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of Age
Started68200
Completed64500
Not completed3700
Withdrew: Withdrawal by subject2500
Withdrew: Lost to follow-up1200

Outcome measures

PrimaryStage I: Competitive Luminex Immunoassay (cLIA) Geometric Mean Titers (GMTs) for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age and 20 to 26 Years of Age: Month 7

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as milli Merck units/mL (mMU/mL).

Time frame:
1 month post vaccination 3 (Month 7)
Reported as:
Geometric mean · mMU/mL
Stage I: Competitive Luminex Immunoassay (cLIA) Geometric Mean Titers (GMTs) for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age and 20 to 26 Years of Age: Month 7
mMU/mL9 to 19 Years of Age20 to 26 Years of Age
Anti-HPV 61129.7 (1069.8 to 1193.0)861.7 (817.5 to 908.4)
Anti-HPV 11926.7 (876.4 to 979.8)702.6 (662.7 to 744.9)
Anti-HPV 164972.3 (4696.9 to 5263.9)3723.7 (3513.0 to 3946.9)
Anti-HPV 181438.4 (1349.0 to 1533.6)1031.6 (964.4 to 1103.6)
Anti-HPV 311161.5 (1093.2 to 1234.2)821.9 (770.5 to 876.7)
Anti-HPV 33664.3 (626.3 to 704.7)497.5 (468.1 to 528.8)
Anti-HPV 45442.9 (415.0 to 472.7)299.1 (279.8 to 319.9)
Anti-HPV 52505.9 (478.4 to 535.0)397.8 (374.4 to 422.8)
Anti-HPV 58725.3 (685.6 to 767.4)535.9 (503.2 to 570.8)
Statistical analysis
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an analysis of variance (ANOVA) model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.31 · 97.5% CI 1.20 to 1.43GMT ratio and confidence interval were calculated using an ANOVA model.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.32 · 97.5% CI 1.20 to 1.45GMT ratio and confidence interval were calculated using an ANOVA model.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.34 · 97.5% CI 1.22 to 1.47GMT ratio and confidence interval were calculated using an ANOVA model.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.39 · 97.5% CI 1.25 to 1.55GMT ratio and confidence interval were calculated using an ANOVA model.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.41 · 97.5% CI 1.28 to 1.56GMT ratio and confidence interval were calculated using an ANOVA model.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.34 · 97.5% CI 1.21 to 1.47GMT ratio and confidence interval were calculated using an ANOVA model.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.48 · 97.5% CI 1.33 to 1.65GMT ratio and confidence interval were calculated using an ANOVA model.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.27 · 97.5% CI 1.16 to 1.40GMT ratio and confidence interval were calculated using an ANOVA model.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.35 · 97.5% CI 1.23 to 1.49GMT ratio and confidence interval were calculated using an ANOVA model.
PrimaryStage I: Percentage of Participants 27 to 45 Years of Age and 20 to 26 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
1 month post vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Stage I: Percentage of Participants 27 to 45 Years of Age and 20 to 26 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7
Percentage of Participants20 to 26 Years of Age27 to 45 Years of Age
Anti-HPV 6 ≥50 mMU/mL100.0 (99.4 to 100.0)100.0 (99.3 to 100.0)
Anti-HPV 11 ≥29 mMU/mL100.0 (99.4 to 100.0)100.0 (99.3 to 100.0)
Anti-HPV 16 ≥41 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 18 ≥59 mMU/mL99.8 (99.0 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 31 ≥29 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 33 ≥22 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 45 ≥15 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 52 ≥20 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 58 ≥15 mMU/mL100.0 (99.4 to 100.0)100.0 (99.3 to 100.0)
Statistical analysis
  • 20 to 26 Years of Age vs 27 to 45 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -1.0 to 0.9Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 20 to 26 Years of Age vs 27 to 45 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -1.0 to 0.9Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 20 to 26 Years of Age vs 27 to 45 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.9 to 0.8Difference in seroconversion percentages and confidence interval was calculated using Miettinen \& Nurminen method.
  • 20 to 26 Years of Age vs 27 to 45 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.2 · 97.5% CI -0.7 to 1.2Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 20 to 26 Years of Age vs 27 to 45 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.9 to 0.8Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 20 to 26 Years of Age vs 27 to 45 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.9 to 0.8Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 20 to 26 Years of Age vs 27 to 45 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.8 to 0.8Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 20 to 26 Years of Age vs 27 to 45 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.9 to 0.9Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 20 to 26 Years of Age vs 27 to 45 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.9 to 0.9Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
PrimaryStage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 12

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
Month 12
Reported as:
Geometric mean · mMU/mL
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 12
mMU/mL9 to 19 Years of Age
Anti-HPV 6420.3 (393.3 to 449.1)
Anti-HPV 11341.9 (320.1 to 365.3)
Anti-HPV 161748.7 (1636.7 to 1868.3)
Anti-HPV 18472.2 (440.6 to 506.1)
Anti-HPV 31403.5 (375.6 to 433.5)
Anti-HPV 33237.7 (221.8 to 254.8)
Anti-HPV 45144.0 (133.4 to 155.3)
Anti-HPV 52187.6 (175.8 to 200.2)
Anti-HPV 58272.5 (255.5 to 290.7)
PrimaryStage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 24

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
Month 24
Reported as:
Geometric mean · mMU/mL
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 24
mMU/mL9 to 19 Years of Age
Anti-HPV 6210.2 (196.4 to 225.0)
Anti-HPV 11172.2 (160.7 to 184.5)
Anti-HPV 16774.8 (717.2 to 837.1)
Anti-HPV 18226.9 (211.8 to 243.0)
Anti-HPV 31205.3 (190.4 to 221.4)
Anti-HPV 33120.4 (112.2 to 129.2)
Anti-HPV 4572.1 (66.8 to 77.8)
Anti-HPV 5297.5 (91.3 to 104.2)
Anti-HPV 58125.8 (117.0 to 135.3)
PrimaryStage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 36

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
Month 36
Reported as:
Geometric mean · mMU/mL
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 36
mMU/mL9 to 19 Years of Age
Anti-HPV 6172.6 (161.6 to 184.4)
Anti-HPV 11136.5 (127.6 to 146.0)
Anti-HPV 16600.5 (554.3 to 650.6)
Anti-HPV 18178.0 (166.3 to 190.5)
Anti-HPV 31166.9 (154.7 to 180.0)
Anti-HPV 3395.1 (88.6 to 102.1)
Anti-HPV 4556.9 (52.8 to 61.4)
Anti-HPV 5278.1 (73.2 to 83.4)
Anti-HPV 58100.9 (93.9 to 108.5)
PrimaryStage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 48

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
Month 48
Reported as:
Geometric mean · mMU/mL
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 48
mMU/mL9 to 19 Years of Age
Anti-HPV 6170.3 (158.9 to 182.6)
Anti-HPV 11123.4 (115.0 to 132.3)
Anti-HPV 16612.6 (568.8 to 659.8)
Anti-HPV 18151.9 (140.1 to 164.8)
Anti-HPV 31165.6 (153.2 to 178.9)
Anti-HPV 3387.9 (81.4 to 94.9)
Anti-HPV 4553.5 (49.4 to 57.9)
Anti-HPV 5275.3 (70.5 to 80.4)
Anti-HPV 5897.1 (90.5 to 104.2)
PrimaryStage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 60

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
Month 60
Reported as:
Geometric mean · mMU/mL
Stage II: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 60
mMU/mL9 to 19 Years of Age
Anti-HPV 6154.2 (143.5 to 165.6)
Anti-HPV 11111.3 (103.5 to 119.6)
Anti-HPV 16541.7 (502.0 to 584.5)
Anti-HPV 18132.9 (122.5 to 144.1)
Anti-HPV 31147.1 (135.9 to 159.2)
Anti-HPV 3379.0 (73.1 to 85.3)
Anti-HPV 4548.3 (44.5 to 52.4)
Anti-HPV 5268.6 (64.1 to 73.3)
Anti-HPV 5886.8 (80.6 to 93.4)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 12

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 12
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 12
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥50 mMU/mL99.5 (98.6 to 99.9)
Anti-HPV 11 ≥29 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 16 ≥41 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 18 ≥59 mMU/mL99.0 (97.9 to 99.6)
Anti-HPV 31 ≥29 mMU/mL99.4 (98.4 to 99.8)
Anti-HPV 33 ≥22 mMU/mL99.5 (98.6 to 99.9)
Anti-HPV 45 ≥15 mMU/mL98.9 (97.8 to 99.6)
Anti-HPV 52 ≥20 mMU/mL99.7 (98.9 to 100.0)
Anti-HPV 58 ≥15 mMU/mL100.0 (99.4 to 100.0)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 24

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 24
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 24
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥50 mMU/mL96.4 (94.6 to 97.7)
Anti-HPV 11 ≥29 mMU/mL98.3 (96.9 to 99.1)
Anti-HPV 16 ≥41 mMU/mL99.1 (98.0 to 99.7)
Anti-HPV 18 ≥59 mMU/mL95.7 (93.8 to 97.1)
Anti-HPV 31 ≥29 mMU/mL98.0 (96.6 to 98.9)
Anti-HPV 33 ≥22 mMU/mL98.0 (96.5 to 98.9)
Anti-HPV 45 ≥15 mMU/mL96.8 (95.1 to 98.0)
Anti-HPV 52 ≥20 mMU/mL96.9 (95.3 to 98.1)
Anti-HPV 58 ≥15 mMU/mL98.0 (96.6 to 98.9)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 36

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥65, 37, 79, 85, 46, 26, 21, 30 and 31 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 36
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 36
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥65 mMU/mL87.3 (84.5 to 89.9)
Anti-HPV 11 ≥37 mMU/mL94.5 (92.4 to 96.1)
Anti-HPV 16 ≥79 mMU/mL97.0 (95.4 to 98.2)
Anti-HPV 18 ≥85 mMU/mL80.5 (77.1 to 83.5)
Anti-HPV 31 ≥46 mMU/mL90.5 (88.0 to 92.7)
Anti-HPV 33 ≥26 mMU/mL94.8 (92.8 to 96.4)
Anti-HPV 45 ≥21 mMU/mL84.9 (81.9 to 87.6)
Anti-HPV 52 ≥30 mMU/mL86.9 (84.0 to 89.4)
Anti-HPV 58 ≥31 mMU/mL90.2 (87.5 to 92.4)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 48

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥34, 25, 32, 26, 15, 10, 10, 14 and 10 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 48
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 48
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥34 mMU/mL94.2 (92.0 to 95.9)
Anti-HPV 11 ≥25 mMU/mL95.9 (94.1 to 97.4)
Anti-HPV 16 ≥32 mMU/mL99.1 (98.0 to 99.7)
Anti-HPV 18 ≥26 mMU/mL92.3 (89.8 to 94.3)
Anti-HPV 31 ≥15 mMU/mL98.3 (96.9 to 99.1)
Anti-HPV 33 ≥10 mMU/mL97.4 (95.8 to 98.5)
Anti-HPV 45 ≥10 mMU/mL92.7 (90.4 to 94.6)
Anti-HPV 52 ≥14 mMU/mL96.8 (95.1 to 98.0)
Anti-HPV 58 ≥10 mMU/mL98.5 (97.3 to 99.3)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 60

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥34, 25, 32, 26, 15, 10, 10, 14 and 10 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 60
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 60
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥34 mMU/mL92.5 (90.2 to 94.5)
Anti-HPV 11 ≥25 mMU/mL93.5 (91.3 to 95.4)
Anti-HPV 16 ≥32 mMU/mL98.9 (97.7 to 99.5)
Anti-HPV 18 ≥26 mMU/mL90.3 (87.6 to 92.5)
Anti-HPV 31 ≥15 mMU/mL97.6 (96.0 to 98.6)
Anti-HPV 33 ≥10 mMU/mL96.2 (94.4 to 97.6)
Anti-HPV 45 ≥10 mMU/mL89.7 (87.0 to 91.9)
Anti-HPV 52 ≥14 mMU/mL95.3 (93.3 to 96.8)
Anti-HPV 58 ≥10 mMU/mL97.9 (96.4 to 98.9)
PrimaryStage II: Immunoglobulin G Luminex Immunoassay (IgG LIA) GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 12

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL. Although the same name (mMU/mL) is used for the unit of measurement in both cLIA and IgG LIA, the 'cLIA mMU/mL' and the 'IgG LIA mMU/mL' are actually different units of measurement and cannot be directly compared.

Time frame:
Month 12
Reported as:
Geometric mean · mMU/mL
Stage II: Immunoglobulin G Luminex Immunoassay (IgG LIA) GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 12
mMU/mL9 to 19 Years of Age
Anti-HPV 6355.1 (329.4 to 382.7)
Anti-HPV 11290.5 (270.1 to 312.4)
Anti-HPV 161505.2 (1405.6 to 1611.9)
Anti-HPV 18340.1 (314.5 to 367.8)
Anti-HPV 31331.7 (307.2 to 358.2)
Anti-HPV 33194.7 (180.6 to 210.0)
Anti-HPV 45112.1 (103.3 to 121.7)
Anti-HPV 52153.3 (142.7 to 164.8)
Anti-HPV 58230.0 (214.6 to 246.4)
PrimaryStage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 24

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
Month 24
Reported as:
Geometric mean · mMU/mL
Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 24
mMU/mL9 to 19 Years of Age
Anti-HPV 6186.3 (172.2 to 201.5)
Anti-HPV 11159.0 (147.3 to 171.7)
Anti-HPV 16750.8 (695.2 to 810.8)
Anti-HPV 18153.6 (140.4 to 168.0)
Anti-HPV 31174.8 (161.1 to 189.6)
Anti-HPV 3399.1 (91.3 to 107.5)
Anti-HPV 4558.4 (53.5 to 63.9)
Anti-HPV 5282.6 (76.7 to 89.1)
Anti-HPV 58115.2 (106.8 to 124.4)
PrimaryStage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 36

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
Month 36
Reported as:
Geometric mean · mMU/mL
Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 36
mMU/mL9 to 19 Years of Age
Anti-HPV 6143.2 (132.0 to 155.5)
Anti-HPV 11121.9 (112.5 to 132.2)
Anti-HPV 16566.1 (521.8 to 614.2)
Anti-HPV 18112.3 (102.1 to 123.4)
Anti-HPV 31137.3 (126.1 to 149.5)
Anti-HPV 3375.4 (69.2 to 82.1)
Anti-HPV 4544.2 (40.3 to 48.4)
Anti-HPV 5265.0 (60.2 to 70.3)
Anti-HPV 5890.0 (83.1 to 97.6)
PrimaryStage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 48

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
Month 48
Reported as:
Geometric mean · mMU/mL
Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 48
mMU/mL9 to 19 Years of Age
Anti-HPV 6121.4 (111.9 to 131.8)
Anti-HPV 11104.4 (96.3 to 113.2)
Anti-HPV 16491.4 (452.7 to 533.4)
Anti-HPV 1896.0 (87.2 to 105.7)
Anti-HPV 31122.0 (112.0 to 133.0)
Anti-HPV 3365.8 (60.4 to 71.8)
Anti-HPV 4538.7 (35.4 to 42.4)
Anti-HPV 5256.6 (52.3 to 61.3)
Anti-HPV 5879.7 (73.5 to 86.5)
PrimaryStage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 60

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
Month 60
Reported as:
Geometric mean · mMU/mL
Stage II: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 60
mMU/mL9 to 19 Years of Age
Anti-HPV 6106.8 (98.1 to 116.3)
Anti-HPV 1191.3 (83.9 to 99.2)
Anti-HPV 16433.6 (398.2 to 472.2)
Anti-HPV 1881.9 (74.2 to 90.3)
Anti-HPV 31106.1 (97.1 to 115.9)
Anti-HPV 3358.3 (53.4 to 63.6)
Anti-HPV 4533.6 (30.6 to 36.9)
Anti-HPV 5249.6 (45.7 to 54.0)
Anti-HPV 5870.8 (65.0 to 77.0)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 12

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 12
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 12
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥9 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 11 ≥6 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 16 ≥5 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 18 ≥5 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 31 ≥3 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 33 ≥4 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 45 ≥3 mMU/mL99.8 (99.1 to 100.0)
Anti-HPV 52 ≥5 mMU/mL99.8 (99.1 to 100.0)
Anti-HPV 58 ≥5 mMU/mL99.8 (99.1 to 100.0)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 24

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 24
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 24
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥9 mMU/mL99.8 (99.1 to 100.0)
Anti-HPV 11 ≥6 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 16 ≥5 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 18 ≥5 mMU/mL99.4 (98.4 to 99.8)
Anti-HPV 31 ≥3 mMU/mL99.8 (99.1 to 100.0)
Anti-HPV 33 ≥4 mMU/mL99.8 (99.1 to 100.0)
Anti-HPV 45 ≥3 mMU/mL99.1 (98.0 to 99.7)
Anti-HPV 52 ≥5 mMU/mL99.8 (99.1 to 100.0)
Anti-HPV 58 ≥5 mMU/mL99.5 (98.6 to 99.9)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 36

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 36
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 36
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥9 mMU/mL99.7 (98.8 to 100.0)
Anti-HPV 11 ≥6 mMU/mL99.7 (98.8 to 100.0)
Anti-HPV 16 ≥5 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 18 ≥5 mMU/mL98.7 (97.4 to 99.4)
Anti-HPV 31 ≥3 mMU/mL99.8 (99.1 to 100.0)
Anti-HPV 33 ≥4 mMU/mL99.4 (98.4 to 99.8)
Anti-HPV 45 ≥3 mMU/mL98.4 (97.1 to 99.2)
Anti-HPV 52 ≥5 mMU/mL99.2 (98.1 to 99.7)
Anti-HPV 58 ≥5 mMU/mL99.0 (97.9 to 99.6)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 48

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 48
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 48
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥9 mMU/mL99.2 (98.1 to 99.7)
Anti-HPV 11 ≥6 mMU/mL99.2 (98.1 to 99.7)
Anti-HPV 16 ≥5 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 18 ≥5 mMU/mL98.5 (97.2 to 99.3)
Anti-HPV 31 ≥3 mMU/mL99.5 (98.6 to 99.9)
Anti-HPV 33 ≥4 mMU/mL98.5 (97.2 to 99.3)
Anti-HPV 45 ≥3 mMU/mL98.6 (97.3 to 99.3)
Anti-HPV 52 ≥5 mMU/mL98.7 (97.5 to 99.4)
Anti-HPV 58 ≥5 mMU/mL99.0 (97.9 to 99.6)
PrimaryStage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 60

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
Month 60
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 60
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥9 mMU/mL99.0 (97.9 to 99.6)
Anti-HPV 11 ≥6 mMU/mL99.0 (97.9 to 99.6)
Anti-HPV 16 ≥5 mMU/mL100.0 (99.4 to 100.0)
Anti-HPV 18 ≥5 mMU/mL97.5 (95.9 to 98.6)
Anti-HPV 31 ≥3 mMU/mL99.7 (98.8 to 100.0)
Anti-HPV 33 ≥4 mMU/mL98.2 (96.8 to 99.1)
Anti-HPV 45 ≥3 mMU/mL97.9 (96.4 to 98.9)
Anti-HPV 52 ≥5 mMU/mL98.2 (96.8 to 99.1)
Anti-HPV 58 ≥5 mMU/mL98.7 (97.4 to 99.4)
SecondaryStage I: Percentage of Participants 9 to 19 Years of Age and 20 to 26 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
1 month post vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Stage I: Percentage of Participants 9 to 19 Years of Age and 20 to 26 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7
Percentage of Participants9 to 19 Years of Age20 to 26 Years of Age
Anti-HPV 6 ≥50 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 11 ≥29 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 16 ≥41 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 18 ≥59 mMU/mL100.0 (99.4 to 100.0)99.8 (99.0 to 100.0)
Anti-HPV 31 ≥29 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 33 ≥22 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 45 ≥15 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 52 ≥20 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 58 ≥15 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Statistical analysis
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.8 to 0.9Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.8 to 0.9Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.8 to 0.8Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.2 · 97.5% CI -0.6 to 1.2Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.8 to 0.8Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.8 to 0.8Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.8 to 0.8Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.8 to 0.9Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
  • 9 to 19 Years of Age vs 20 to 26 Years of Age · Miettinen & Nurminen method · p = < 0.0001 (p-value was calculated using Miettinen \& Nurminen method.) · Difference of seroconversion percentages: 0.0 · 97.5% CI -0.8 to 0.9Difference in seroconversion percentages and confidence interval were calculated using Miettinen \& Nurminen method.
SecondaryStage I: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 15 Years of Age and 20 to 26 Years of Age: Month 7

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type were expressed as mMU/mL. As pre-specified per protocol, participants 20 to 26 years of age and a subset of participants 9 to 15 years of age were included in the analysis.

Time frame:
1 month post vaccination 3 (Month 7)
Reported as:
Geometric mean · mMU/mL
Stage I: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 15 Years of Age and 20 to 26 Years of Age: Month 7
mMU/mL20 to 26 Years of Age9 to 19 Years of Age
Anti-HPV 6861.7 (817.5 to 908.4)1201.1 (1123.6 to 1284.0)
Anti-HPV 11702.6 (662.7 to 744.9)981.6 (917.5 to 1050.2)
Anti-HPV 163723.7 (3513.0 to 3946.9)5279.6 (4943.8 to 5638.3)
Anti-HPV 181031.6 (964.4 to 1103.6)1582.4 (1469.4 to 1704.1)
Anti-HPV 31821.9 (770.5 to 876.7)1253.1 (1167.7 to 1344.9)
Anti-HPV 33497.5 (468.1 to 528.8)699.6 (653.5 to 748.9)
Anti-HPV 45299.1 (279.8 to 319.9)490.5 (454.3 to 529.6)
Anti-HPV 52397.8 (374.4 to 422.8)535.1 (501.4 to 571.1)
Anti-HPV 58535.9 (503.2 to 570.8)771.5 (721.8 to 824.6)
Statistical analysis
  • 20 to 26 Years of Age vs 9 to 19 Years of Age · ANOVA · p = < 0.001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.39 · 97.5% CI 1.27 to 1.53GMT ratio and confidence interval were calculated using an ANOVA model.
  • 20 to 26 Years of Age vs 9 to 19 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.40 · 97.5% CI 1.26 to 1.55GMT ratio and confidence interval were calculated using an ANOVA model.
  • 20 to 26 Years of Age vs 9 to 19 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.42 · 97.5% CI 1.28 to 1.57GMT ratio and confidence interval were calculated using an ANOVA model.
  • 20 to 26 Years of Age vs 9 to 19 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.53 · 97.5% CI 1.37 to 1.72GMT ratio and confidence interval were calculated using an ANOVA model.
  • 20 to 26 Years of Age vs 9 to 19 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.52 · 97.5% CI 1.37 to 1.70GMT ratio and confidence interval were calculated using an ANOVA model.
  • 20 to 26 Years of Age vs 9 to 19 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.41 · 97.5% CI 1.27 to 1.56GMT ratio and confidence interval were calculated using an ANOVA model.
  • 20 to 26 Years of Age vs 9 to 19 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.64 · 97.5% CI 1.46 to 1.84GMT ratio and confidence interval were calculated using an ANOVA model.
  • 20 to 26 Years of Age vs 9 to 19 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.35 · 97.5% CI 1.21 to 1.49GMT ratio and confidence interval were calculated using an ANOVA model.
  • 20 to 26 Years of Age vs 9 to 19 Years of Age · ANOVA · p = < 0.0001 (p-value was calculated using an ANOVA model with a response of log individual titers and fixed effect for group.) · Gmt ratio: 1.44 · 97.5% CI 1.29 to 1.60GMT ratio and confidence interval were calculated using an ANOVA model.
SecondaryStage I: Percentage of Participants 9 to 15 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using cLIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥50, 29, 41, 59, 29, 22, 15, 20, and 15 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively. As pre-specified per protocol, a subset of participants 9 to 15 years of age were included in the analysis.

Time frame:
1 month post vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Stage I: Percentage of Participants 9 to 15 Years of Age Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7
Percentage of Participants9 to 19 Years of Age
Anti-HPV 6 ≥50 mMU/mL100.0 (99.1 to 100.0)
Anti-HPV 11 ≥29 mMU/mL100.0 (99.1 to 100.0)
Anti-HPV 16 ≥41 mMU/mL100.0 (99.2 to 100.0)
Anti-HPV 18 ≥59 mMU/mL100.0 (99.1 to 100.0)
Anti-HPV 31 ≥29 mMU/mL100.0 (99.2 to 100.0)
Anti-HPV 33 ≥22 mMU/mL100.0 (99.1 to 100.0)
Anti-HPV 45 ≥15 mMU/mL100.0 (99.2 to 100.0)
Anti-HPV 52 ≥20 mMU/mL100.0 (99.1 to 100.0)
Anti-HPV 58 ≥15 mMU/mL100.0 (99.1 to 100.0)
SecondaryStage I: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 27 to 45 Years of Age: Month 7

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using cLIA. The HPV-9 cLIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type were expressed as mMU/mL.

Time frame:
1 month post vaccination 3 (Month 7)
Reported as:
Geometric mean · mMU/mL
Stage I: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 27 to 45 Years of Age: Month 7
mMU/mL27 to 45 Years of Age
Anti-HPV 6784.1 (738.9 to 832.1)
Anti-HPV 11634.7 (596.1 to 675.8)
Anti-HPV 163175.0 (2983.0 to 3379.5)
Anti-HPV 18838.9 (783.8 to 897.8)
Anti-HPV 31699.9 (658.3 to 744.1)
Anti-HPV 33422.7 (396.9 to 450.1)
Anti-HPV 45245.1 (229.8 to 261.5)
Anti-HPV 52342.1 (322.2 to 363.2)
Anti-HPV 58435.2 (408.1 to 464.2)
SecondaryStage I: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age, 20 to 26 Years of Age, and 27 to 45 Years of Age: Month 7

Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using IgG LIA. The HPV-9 IgG LIA assay was used to quantify the antibodies. This assay evaluated the serological response before and after 9vHPV vaccination and measured HPV infection-induced antibodies. The GMT for each HPV type was expressed as mMU/mL.

Time frame:
1 month post vaccination 3 (Month 7)
Reported as:
Geometric mean · mMU/mL
Stage I: IgG LIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age, 20 to 26 Years of Age, and 27 to 45 Years of Age: Month 7
mMU/mL9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of Age
Anti-HPV 61177.1 (1105.1 to 1253.7)835.9 (785.7 to 889.3)717.2 (668.3 to 769.8)
Anti-HPV 11939.9 (884.2 to 999.1)670.6 (628.8 to 715.2)566.1 (526.0 to 609.1)
Anti-HPV 164746.8 (4473.9 to 5036.4)3435.0 (3232.2 to 3650.5)2867.6 (2685.8 to 3061.7)
Anti-HPV 181303.8 (1219.5 to 1393.8)910.3 (848.6 to 976.5)741.7 (690.6 to 796.5)
Anti-HPV 311082.5 (1016.4 to 1152.9)744.2 (695.5 to 796.2)630.2 (589.5 to 673.6)
Anti-HPV 33647.1 (607.3 to 689.5)461.7 (433.0 to 492.4)384.5 (359.0 to 411.9)
Anti-HPV 45397.9 (371.7 to 425.9)260.7 (243.0 to 279.6)213.7 (199.6 to 228.8)
Anti-HPV 52478.8 (450.7 to 508.8)354.7 (332.0 to 379.0)278.3 (259.2 to 298.8)
Anti-HPV 58698.8 (659.0 to 741.1)501.0 (469.4 to 534.8)399.3 (373.2 to 427.2)
SecondaryStage I: Percentage of Participants 9 to 19 Years of Age, 20 to 26 Years of Age, and 27 to 45 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7

The percentage of participants who are seropositive for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined using IgG LIA. Seroconversion was defined as changing serostatus from seronegative at baseline (Day 1) to seropositive at 1 month after last dose. Cutoff values for HPV seropositivity are ≥9, 6, 5, 5, 3, 4, 3, 5 and 5 mMU/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.

Time frame:
1 month post vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Stage I: Percentage of Participants 9 to 19 Years of Age, 20 to 26 Years of Age, and 27 to 45 Years of Age Who Are Seropositive by IgG LIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7
Percentage of Participants9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of Age
Anti-HPV 6 ≥9 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)100.0 (99.3 to 100.0)
Anti-HPV 11 ≥6 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)100.0 (99.3 to 100.0)
Anti-HPV 16 ≥5 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 18 ≥5 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 31 ≥3 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 33 ≥4 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 45 ≥3 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 52 ≥5 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)
Anti-HPV 58 ≥5 mMU/mL100.0 (99.4 to 100.0)100.0 (99.4 to 100.0)100.0 (99.3 to 100.0)
SecondaryStage I: Percentage of Participants Who Experience at Least 1 Solicited Injection-site Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. The participant or the parent/guardian of the participant was to record the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 8 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, swelling and induration) is reported.

Time frame:
Up to 8 days post any vaccination (up to ~Day 192)
Reported as:
Number · Percentage of Participants
Stage I: Percentage of Participants Who Experience at Least 1 Solicited Injection-site Adverse Event (AE)
Percentage of Participants9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of Age
Injection site pain39.1 ± 35.444.5 ± 40.639.1 ± 35.3
Injection site erythema9.3 ± 7.211.1 ± 8.87.4 ± 5.5
Injection site swelling8.1 ± 6.28.9 ± 6.85.4 ± 3.8
Injection site induration6.3 ± 4.68.0 ± 6.06.0 ± 4.3
SecondaryStage I: Percentage of Participants Who Experience at Least 1 Systemic AE

An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. The percentage of participants with a systemic AE is reported.

Time frame:
Up to 31 days post any vaccination (Up to ~Month 7)
Reported as:
Number · Percentage of Participants
Stage I: Percentage of Participants Who Experience at Least 1 Systemic AE
Percentage of Participants9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of Age
Stage I: Percentage of Participants Who Experience at Least 1 Systemic AE50.9 ± 47.157.1 ± 53.243.4 ± 39.5
SecondaryStage I: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. The percentage of participants that experienced 1 or more SAEs is reported.

Time frame:
Day 1 to Month 7
Reported as:
Number · Percentage of Participants
Stage I: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)
Percentage of Participants9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of Age
Stage I: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)1.3 (0.6 to 2.5)2.6 (1.5 to 4.2)2.6 (1.5 to 4.2)
SecondaryStage I: Percentage of Participants With Elevated Axillary Temperature (≥37.1 C)

Participant or participant's legally acceptable representative will be asked to record axillary temperature in the evening after each study vaccination and daily, at the same time of day whenever possible, for 8 days after each study vaccination in the VRC. The percentage of participant's who had an axillary temperature ≥37.1°C is reported.

Time frame:
Up to 8 days post any vaccination (Up to ~Day 192)
Reported as:
Number · Percentage of Participants
Stage I: Percentage of Participants With Elevated Axillary Temperature (≥37.1 C)
Percentage of Participants9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of Age
≥37.1°C (98.8°F) and <37.6°C (99.7°F)20.8 ± 17.823.8 ± 20.611.7 ± 9.3
≥37.6°C (99.7°F) and <39.1°C (102.4°F)2.2 ± 1.22.0 ± 1.10.5 ± 0.1
≥39.1°C (102.4°F)0.3 ± 0.00.2 ± 0.00.0 ± 0.0
SecondaryStage II: Percentage of Participants 9 to 19 Years of Age Who Experience at Least 1 Serious Adverse Event (SAE): Month 7 to Month 60

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. The percentage of participants that experienced 1 or more SAEs is reported.

Time frame:
Month 7 to Month 60
Reported as:
Number · Percentage of Participants
Stage II: Percentage of Participants 9 to 19 Years of Age Who Experience at Least 1 Serious Adverse Event (SAE): Month 7 to Month 60
Percentage of Participants9 to 19 Years of Age
Stage II: Percentage of Participants 9 to 19 Years of Age Who Experience at Least 1 Serious Adverse Event (SAE): Month 7 to Month 601.5

Adverse events

Collected over Stage I: Day 1 to Month 7; Stage II: Post Month 7 to Month 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage I: 9 to 19 Years of Age0/690 (0%)9/688 (1.3%)411/688 (59.7%)
Stage I: 20 to 26 Years of Age0/650 (0%)17/650 (2.6%)424/650 (65.2%)
Stage I: 27 to 45 Years of Age0/650 (0%)17/650 (2.6%)346/650 (53.2%)
Stage II: 9 to 19 Years of Age0/682 (0%)10/682 (1.5%)0/682 (0%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventStage I: 9 to 19 Years of AgeStage I: 20 to 26 Years of AgeStage I: 27 to 45 Years of AgeStage II: 9 to 19 Years of Age
Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6883/6500/6500/682
Abortion missedPregnancy, puerperium and perinatal conditions0/6880/6502/6500/682
Cervical dysplasiaReproductive system and breast disorders0/6880/6502/6500/682
Uterine diverticulumReproductive system and breast disorders0/6880/6502/6500/682
Supraventricular tachycardiaCardiac disorders0/6881/6500/6501/682
Retinal detachmentEye disorders0/6880/6501/6500/682
HaemoperitoneumGastrointestinal disorders0/6880/6501/6500/682
Inflammatory bowel diseaseGastrointestinal disorders0/6880/6501/6500/682
Tooth impactedGastrointestinal disorders0/6881/6500/6500/682
Cholecystitis chronicHepatobiliary disorders0/6881/6500/6500/682
Most frequent other events
Most frequent other events
EventStage I: 9 to 19 Years of AgeStage I: 20 to 26 Years of AgeStage I: 27 to 45 Years of AgeStage II: 9 to 19 Years of Age
Injection site painGeneral disorders270/688294/650259/6500/682
PyrexiaGeneral disorders172/688175/65085/6500/682
Injection site erythemaGeneral disorders64/68873/65048/6500/682
Injection site swellingGeneral disorders60/68863/65038/6500/682
Injection site indurationGeneral disorders46/68858/65045/6500/682
CoughRespiratory, thoracic and mediastinal disorders51/68835/65027/6500/682
Oropharyngeal painRespiratory, thoracic and mediastinal disorders45/68844/65022/6500/682
RhinorrhoeaRespiratory, thoracic and mediastinal disorders42/68840/65019/6500/682

Baseline characteristics

Age, Continuous
Age, Continuous(years)9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of AgeTotal
Mean14.0 ± 3.023.1 ± 1.735.5 ± 5.124.0 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of AgeTotal
Female6906506501990
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of AgeTotal
Hispanic or Latino0000
Not Hispanic or Latino6906506501990
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)9 to 19 Years of Age20 to 26 Years of Age27 to 45 Years of AgeTotal
American Indian or Alaska Native0000
Asian6906506501990
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

2 sites
  • Kaihua country Center for Disease Control and Prevention ( Site 0002)
    Quzhou, Zhejiang 324300, China
  • Shaoxing keqiao center for disease prevention and control ( Site 0001)
    Shaoxing, Zhejiang 312030, China
09

References and documents

Publications

  • Lv H, Wang S, Liang Z, Yu W, Yan C, Chen Y, Hu X, Fu R, Zheng M, Group T, Luxembourg A, Liao X, Chen Z. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study. Vaccine. 2022 May 20;40(23):3263-3271. doi: 10.1016/j.vaccine.2022.02.061. Epub 2022 Apr 26. PubMed 35487814 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Feb 2025, 70 months.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 70 months is above that.

Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2019
First posted
Apr 4, 2019
StartActual
Apr 27, 2019
Primary completionActual
Feb 28, 2025
CompletionActual
Feb 28, 2025
Results first posted
Apr 6, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03903562
Responsible party
Sponsor
First posted
Apr 4, 2019
Start date
Apr 27, 2019
Primary completion
Feb 28, 2025
Completion
Feb 28, 2025
Results posted
Apr 6, 2026
Last update
Apr 6, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion